integrase-based regimen
Showing 1 - 25 of >10,000
Human Immunodeficiency Virus Trial in Oakland Park (Symtuza)
Terminated
- Human Immunodeficiency Virus
-
Oakland Park, FloridaMidland Research Group, Inc
Dec 3, 2021
HIV Reservoir, Inflammation and Microbiota Footprint of PLWH
Recruiting
- HIV Infections
- Stool sampling
- Blood plasma collection
-
Marseille, FranceHôpital Européen Marseille
Jul 26, 2022
Eribulin-Based Regimen Versus Other Chemotherpy in
Active, not recruiting
- Breast Cancer
- Eribulin-Based Regimen
- +2 more
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Jul 18, 2023
HIV Trial in Baltimore (Switch to Maraviroc + Raltegravir or Dolutegravir)
Completed
- HIV
- Switch to Maraviroc + Raltegravir or Dolutegravir
-
Baltimore, MarylandUniversity of Maryland, Institute of Human Virology
Oct 5, 2021
HIV Trial in Paris (Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine)
Not yet recruiting
- HIV Infections
- Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
-
Paris, Ile De France, FranceChristine Katlama
Jul 26, 2022
Helicobacter Pylori Infection Trial in Damascus (sequential, Levofloxacin 500Mg Oral Tablet)
Not yet recruiting
- Helicobacter Pylori Infection
- sequential
- Levofloxacin 500Mg Oral Tablet
-
Damascus, Syrian Arab RepublicGeneral Assembly of Damascus Hospital
Sep 27, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Sep 12, 2023
Erythema, Radiation Therapy, Secondary Skin Reactions Trial in Fort Myers (VS-200Cr, Standard of care)
Not yet recruiting
- Erythema
- Radiation Therapy, Secondary Skin Reactions
- VS-200Cr
- Standard of care
-
Fort Myers, FloridaAdvocate Radiation Oncology
Aug 23, 2023
Gaucher Disease Type 1 Trial in Jerusalem (Enzyme replacement therapy for Gaucher disease in combination with altus care
Completed
- Gaucher Disease Type 1
- Enzyme replacement therapy for Gaucher disease in combination with altus care application
-
Jerusalem, IsraelHebrew university
Sep 18, 2023
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Homologous Recombination Deficiency
- (no location specified)
Oct 18, 2023
Liver Diseases Trial in New Delhi (12 weeks exercise, Standard Medical Treatment)
Not yet recruiting
- Liver Diseases
- 12 weeks exercise
- Standard Medical Treatment
-
New Delhi, Delhi, IndiaInstitute of Liver & Biliary Sciences
Mar 14, 2023
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Completed
- Infection, Human Immunodeficiency Virus I
- DTG based ARV regimen with ABC
- +4 more
- (no location specified)
Feb 5, 2020
Myeloid Malignancies Trial in Chendu (fractionated busulfan-based conditioning regimen)
Recruiting
- Myeloid Malignancies
- fractionated busulfan-based conditioning regimen
-
Chendu, Sichuan, ChinaWest China Hospital, Sichuan University
Mar 29, 2023
Valvular Heart Disease Trial (HBCR hands-off, HBCR interactive)
Not yet recruiting
- Valvular Heart Disease
- HBCR hands-off
- HBCR interactive
- (no location specified)
Oct 12, 2023
Newly-diagnosed PCNSL Treated WithMethotrexate and
Active, not recruiting
- Primary Central Nervous System Lymphoma
-
Shanghai, ChinaDepartment of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023
Helicobacter Pylori Infection Trial in Alexandria (standard Clarithromycin triple therapy, Vonoprazan triple therapy, Vonoprazan
Recruiting
- Helicobacter Pylori Infection
- standard Clarithromycin triple therapy
- +2 more
-
Alexandria, EgyptAlexandria University outpatient clinics
Nov 7, 2022
Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)
Recruiting
- Plasma Cell Leukemia
- anti-BCMA CAR-T
- VRD-based regimen
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation, Chronic Myeloid Leukemia -
Recruiting
- Chronic Myeloid Leukemia in Myeloid Blast Crisis
- +3 more
- based decitabine and olverembatinib（HQP1351)chemotherapy
-
Guanzhou, ChinaDepartment of Hematology, Nanfang Hospital, Southern Medical Uni
Dec 6, 2022
Renal Allograft Recipients Trial in Worldwide (Belatacept, Tacrolimus, Cyclosporine A)
Recruiting
- Renal Allograft Recipients
- Belatacept
- +5 more
-
Birmingham, Alabama
- +14 more
Oct 24, 2022
Biliary Tract Cancer Trial in Worldwide (Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin)
Not yet recruiting
- Biliary Tract Cancer
- Durvalumab
- +7 more
-
Orange, California
- +36 more
Mar 6, 2023
Severely Immunocompromised HIV Patients Trial in Salvador, Rio de Janeiro, Porto Alegre (Dolutegravir 50 mg, Efavirenz-based
Completed
- Severely Immunocompromised HIV Patients
- Dolutegravir 50 mg
- Efavirenz-based regimens
-
Salvador, Bahia, Brazil
- +2 more
Mar 15, 2022
Pancreatic Cancer Trial in Modena (LDR, Gem-based doublets, SBRT)
Recruiting
- Pancreatic Cancer
- LDR
- +2 more
-
Modena, MO, ItalyAzienda Ospedaliero-Universitaria Policlinico di Modena
Dec 8, 2022
Breast Cancer Trial in Worthington, Fargo, Sioux Falls (IMRT/VMAT-Based Accelerated Partial Breast Irradiation)
Recruiting
- Breast Cancer
- IMRT/VMAT-Based Accelerated Partial Breast Irradiation
-
Worthington, Minnesota
- +2 more
Nov 11, 2022
Vitamin D Deficiency, End Stage Renal Disease Trial (ergocalciferol supplementation, dialysis techniques, sunlight exposure
Not yet recruiting
- Vitamin D Deficiency
- End Stage Renal Disease
- ergocalciferol supplementation
- +2 more
- (no location specified)
Jun 26, 2022